PCOS

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Pharmaceutical, Health, Research, A4, GC, Congenital adrenal hyperplasia, Administration, PCOS, P-value, GCS, Patient, Cash, Șaeș, Spruce, Outline, CAH, Clinical trial, Safety, Hyperandrogenism, Polycystic ovary syndrome, ULN, Research and development, Food, FDA, Pharmaceutical industry

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.
  • “We are grateful to all the patients, families, study team and investigators who supported the CAHmelia-203 clinical trial,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, Spruce Biosciences.
  • Non-cash stock-based compensation expense for the year ended December 31, 2023 was $4.6 million compared to $3.6 million in 2022.
  • Net Loss: Net loss for the year ended December 31, 2023 was $47.9 million compared to $46.2 million in 2022.

CCRM FERTILITY WELCOMES REGIONAL DIRECTOR OF CLINICAL REPRODUCTIVE GENETICS, DR. JASMINE ALY, TO JERSEY CITY TEAM

Retrieved on: 
Wednesday, March 27, 2024
ART, WRNMMC, Obstetrics, PCOS, Gynaecology, Obesity, Polycystic disease, Reproductive Sciences, Science, NHGRI, Genetic distance, FACOG, Genetics, COVID-19, Patient, Empathy, Medical genetics, Cooper University Hospital, Research, African Americans, USUHS, Fibroid, Reproduction, Assisted reproductive technology, IRMS, NIH, Polycystic ovary syndrome, Outline of health sciences, Reproductive endocrinology and infertility, Publication, Fertility, REI, Birth control

JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey. Dr. Aly holds the rare distinction of being a triple-specialized physician as an Obstetrician-Gynecologist, Reproductive Endocrinologist, and Medical Geneticist.

Key Points: 
  • JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey.
  • As Regional Director of Clinical Reproductive Genetics, Dr. Aly will bring her expertise to the CCRM Fertility team and aims to leverage her comprehensive fellowship training in genetics to further advance the field and better serve patients.
  • As an esteemed reproductive endocrinologist, she will utilize cutting-edge  technology and innovative scientific techniques to ensure patient success rates continue to rise.
  • "Dr. Aly's expertise in genetics is an invaluable attribute that will redefine care at CCRM | IRMS," notes CCRM Fertility CEO, Bob LaGalia.

San Diego Fertility Center, an Ivy Fertility Clinic, Hires Dr. Valerie Flores

Retrieved on: 
Wednesday, February 21, 2024
Research, Women, Baby, Maternity, Practice Management, Family, Biotechnology, General Health, Consumer, Health, Science, Fertility preservation, MD, NIH, Physician, Pain, Endometriosis, University of Southern California, Yale University, University, SDFC, PCOS, Patient, Uterus, Brown, Infertility, Medical device

Ivy Fertility, a collaborative network of globally-renowned fertility clinics, has welcomed Valerie Flores, MD to its team of physicians at San Diego Fertility Center (SDFC).

Key Points: 
  • Ivy Fertility, a collaborative network of globally-renowned fertility clinics, has welcomed Valerie Flores, MD to its team of physicians at San Diego Fertility Center (SDFC).
  • “We are thrilled that Dr. Flores will be contributing her talents to our physician team,” said Sandy Chuan, MD, medical director at San Diego Fertility Center.
  • She comes to San Diego Fertility Center from Reproductive Partners Fertility Center in San Diego, is an Assistant Professor Adjunct at Yale University’s School of Medicine.
  • “I admire San Diego Fertility Center and Ivy Fertility for leading our industry by putting compassion and collaboration first,” said Dr. Flores.

The Inner Circle acknowledges Hazem Kanaan, DO as a Pinnacle Lifetime Member

Retrieved on: 
Wednesday, March 6, 2024
Award, UHS, Woman, Inner circle, Multimedia, Education, Obesity, Kennesaw State University, Obstetrics, Kennesaw, Georgia, DSM-IV codes, Lower Rio Grande Valley, Health, University, Human, Mentorship, PCOS, Henry Ford Health, Organization, Patient, Family, Women's health, Knowledge, Politics, Obesity medicine, Nursing

EDINBURG, Texas, March 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Hazem Kanaan, DO is acknowledged as a Pinnacle Lifetime Member for his contributions as an Obstetrician-Gynecologist.

Key Points: 
  • EDINBURG, Texas, March 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Hazem Kanaan, DO is acknowledged as a Pinnacle Lifetime Member for his contributions as an Obstetrician-Gynecologist.
  • His impressive journey through education and medical practice is a testament to his unwavering commitment to women's health and reproductive care.
  • Dr. Kanaan embarked on his academic journey at Kennesaw State University, where he earned his undergraduate degree in Biochemistry with Cum-Laude Honors in 2005.
  • In his personal life, Dr. Kanaan acknowledges the profound impact of his family on his career, considering them a significant career accomplishment.

Boston IVF Welcomes Dr. Meaghan Delaney to its Springfield Fertility Center, Expanding Access to Expert Care in Western Massachusetts

Retrieved on: 
Tuesday, February 20, 2024
Boston University, Texas Children's Hospital, IUI, Hysterosalpingography, Medicine, MD, Telehealth, Semen analysis, IVF, Fertility, PCOS, REI, Patient, Pioneer Valley, Family, Medical Center, HSG, Birth control

SPRINGFIELD, Mass., Feb. 20, 2024 /PRNewswire-PRWeb/ -- Boston IVF, one of the world's most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986, is pleased to announce the addition of reproductive endocrinologist, Dr. Meaghan Delaney, MD to its new fertility center in Springfield, MA.

Key Points: 
  • The addition of Dr. Meaghan Delaney to Boston IVF and its fertility clinic in Springfield enhances the accessibility of prompt reproductive care for those desiring to build a family.
  • "Dr. Delaney's return to western Massachusetts and commitment to patient well-being ensure seamless care, delivering invaluable advantages to our patients," stated David Stern, CEO of Boston IVF.
  • Dr. Delaney transitions to Boston IVF from her position as the Medical Director at the UMass Memorial Fertility Center in Worcester, MA.
  • "Dr. Delaney's return to western Massachusetts and commitment to patient well-being ensure seamless care, delivering invaluable advantages to our patients," stated David Stern, CEO of Boston IVF.

Plant Powered & All Natural Hair Care Brand, BLAQ Luxury Hair, Unveils All New Papaya Paradise Collection to Revolutionize Haircare

Retrieved on: 
Wednesday, February 14, 2024
Collection, Butter, PCOS, Beauty, Cosmetics

ORLANDO, Fla., Feb. 14, 2024 /PRNewswire/ -- BLAQ Luxury Hair, the Black-owned and woman founded plant powered all natural hair care line born from the need to create a solution to the adverse effects of PCOS - a hormone imbalance, is thrilled to announce the launch of their highly anticipated Papaya Paradise Collection today. This exciting expansion brings forth seven innovative products that are set to transform the hair care experience for all those with thick, curly, Type 4 hair.

Key Points: 
  • This exciting expansion brings forth seven innovative products that are set to transform the hair care experience for all those with thick, curly, Type 4 hair.
  • Drawing inspiration from founder Cherice Williams' Jamaican heritage, this new collection incorporates natural ingredients like papaya seed oil and murumuru butter; chosen for their ability to deeply nourish and moisturize hair strands.
  • The Papaya Paradise Collection represents the latest milestone in their commitment to providing top-tier solutions for hair health and beauty.
  • For more information about BLAQ Luxury Hair and their Papaya Paradise Collection, please visit https://blaqluxuryhair.com/search?q=papaya

Boston IVF Welcomes Reproductive Endocrinologist Jamil Mroueh, MD to its Rochester Fertility Center Team

Retrieved on: 
Thursday, February 8, 2024
SUNY Downstate Medical Center, American College, American University, Infertility, Greater, REI, MD, Patient, Fertility, IUI, PCOS, ACOG, Acquisition, Education, State university system, Health, IVF, Birth control

 ROCHESTER, Mass., Feb. 8, 2024 /PRNewswire-PRWeb/ -- Boston IVF, one of the world's most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986, is pleased to announce that reproductive endocrinologist, Jamil Mroueh, MD has joined its fertility center in Rochester, NY.

Key Points: 
  • Dr. Jamil Mroueh's Arrival Bolsters Access to Prompt Reproductive Care at Boston IVF and its Rochester, NY Fertility Center.
  • "Dr. Mroueh's addition to Boston IVF's Rochester, NY fertility center represents a notable advantage for residents of the Greater Rochester Region and Western New York," stated David Stern, CEO of the Boston IVF fertility network.
  • Boston IVF's Rochester fertility center is located at 1561 Long Pond Rd Suite 410, Rochester, NY 14626 .
  • "Dr. Mroueh's addition to Boston IVF's Rochester, NY fertility center represents a notable advantage for residents of the Greater Rochester Region and Western New York," stated David Stern, CEO of the Boston IVF fertility network.

Qi Health Revolutionizes Women's Health with Evidence-Based Chinese Herbal Medicine

Retrieved on: 
Monday, November 27, 2023
Patient, PCOS, TCM, Woman, Telehealth, Infertility, PMS, Prescription, Herbal medicine, Fertility, Inflammation, Health, Endometriosis, Chinese herbology, PMDD, Qi, CHM, Female, Traditional Chinese medicine, Medicinal plants

Qi Health introduces the first evidence-based digital health platform for herbal medicine, revolutionizing women's well-being with natural solutions.

Key Points: 
  • New York, New York--(Newsfile Corp. - November 27, 2023) - Qi Health , a cutting-edge digital health platform dedicated to Chinese Herbal Medicine (CHM) emerges from beta today.
  • By connecting patients with certified Traditional Chinese Medicine (TCM) doctors in the United States through video calls, Qi Health brings a transformative approach to women's healthcare.
  • In a world where Traditional Chinese Medicine often faces skepticism, Qi Health relies on rigorous research and evidence-based care.
  • Qi Health's vision extends beyond individual care; it aspires to make Traditional Chinese Herbal Medicine accessible to everyone with unexplained or untreated health issues.

ŌURA Reaches Milestone of 600+ Partnerships and Integrations as It Builds a Large-Scale Ecosystem

Retrieved on: 
Thursday, November 30, 2023
Software, Biometrics, Biotechnology, General Health, Health, Health Technology, Technology, Other Health, Stress management, Woman, Behavior, Flexible, Entrepreneurship, CGM, Algorithm, Ecosystem, Cycle track, Dashboard, FSA, Growth, API, IOS, Temperature, Health savings account, Abdominal obesity, Flexible spending account, Tag, HDL, Fertility, Menopause, Oura Health, Life, Science, Meditation, Chart, Natural Cycles, Menstrual cycle, Obstetrics, DSM-IV codes, PCOS, Skin temperature, Community, Blood, Currency strap, Partnership, Himawari (satellites), Education, Hypertension, Research, Apple Watch, Learning, HSA, Pregnancy, Metabolism, FDA, Chronotype, Diary, Ready, Set, PrEP, Mindfulness, Thrive Global, Phosphorus, Mobile phone, Birth control, Pharmaceutical industry, Nursing, Medical device, Sleep, Oura, Headspace, Activity, Noom, Strava

We’ve been steadily building a strong partnership ecosystem and adding world-class features into the ŌURA experience,” said Tom Hale, CEO.

Key Points: 
  • We’ve been steadily building a strong partnership ecosystem and adding world-class features into the ŌURA experience,” said Tom Hale, CEO.
  • “ŌURA is becoming an iconic, global brand that is changing the way we think about long-term health and healthspan.
  • ŌURA is doubling down in specific focus areas with partners across several sectors including women’s health, metabolic health, behavioral health, and fitness and lifestyle.
  • These integrations represent a significant portion of new ŌURA members; additionally, ŌURA members who use Natural Cycles are the highest retaining of all ŌURA cohorts.

Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Adolescence, Safety, CAH, Investment, PD, Administration, Patient, Public expenditure, Androstenedione, G&A, Pharmacokinetics, PCOS, A4, R, Research and development, Pharmaceutical industry, Nursing, Cryptocurrency, Adult

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.
  • CAHmelia-203 Study in Adult Classic CAH Completes Target Enrollment: Target enrollment of 72 patients in the company’s CAHmelia-203 clinical trial is complete .
  • Due to substantial patient interest in CAHmelia-203, final enrollment in the study will exceed its original target of 72 patients.
  • Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of September 30, 2023 were $108.0 million.